Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study

(2015) Giovanni Martinelli et al.   Lancet Haematology

Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers

(2014) M. Naveed Shaik et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors

(2014) A. J. Wagner et al.   CLINICAL CANCER RESEARCH

Targeting hedgehog in hematologic malignancy

(2012) D. A. Irvine et al.   BLOOD

Molecular Pathways: The Hedgehog Signaling Pathway in Cancer

(2012) R. McMillan et al.   CLINICAL CANCER RESEARCH

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

(2011) Michael J. Munchhof et al.   ACS Medicinal Chemistry Letters

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

(2009) Chen Zhao et al.   NATURE

Metabolites in safety testing

(2009) Timothy W Robison et al.   Bioanalysis